A retrospective analysis by Li et al. also showed that after 12 weeks of treatment with other csDMARDs (such as sulfasalazine, hydroxychloroquine sulfate, leflunomide) combined with IGU, the DAS28, RF, CRP, ESR, and morning stiffness of RA patients with chronic interstitial pneumonia were significantly improved compared to those before treatment, and the incidence of adverse reactions was low (Hao and Li 2014). This evidence concerns the gene CRP and rheumatoid arthritis.